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Ace K: Acesulfame potassium 
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CO: Cross-over study design 
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PPI: Postprandial insulin response 
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
S: Single-blind 
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SE: Standard Error 
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Background: It has been suggested that low energy sweeteners (LES) may be 2 
associated with an increased risk of metabolic diseases, possibly due to stimulation of 3 
glucose-responsive mechanisms. 4 
Objective: We conducted a systematic review and meta-analysis of human intervention 5 
studies examining the acute effect of LES intake on postprandial glucose (PPG) and 6 
insulin (PPI) responses, in order to comprehensively and objectively quantify these 7 
relationships. 8 
Methods: We systematically searched Medline, OVID FSTA and SCOPUS databases 9 
until January 2020.  Randomized controlled trials comparing acute postprandial effects 10 
on PPG and/or PPI after exposure to LES; either alone, with a meal or other nutrient-11 
containing preloads to the same intervention without LES were eligible for inclusion.  12 
PPG and PPI responses were calculated as mean incremental area under the curve 13 
divided by time.  Meta-analyses were performed using random effects models with 14 
inverse variance weighing.   15 
Results: Twenty-six papers (34 PPG trials and 29 PPI trials) were included.  There were 16 
no differences in the effect of LES on PPG and PPI responses compared to control 17 
interventions.  Pooled effects of LES intake on the mean change difference in PPG and 18 
PPI were -0.02 mmol/l [95% CI -0.09, 0.05] and -2.39 pmol/l [95%CI -11.83, 7.05] 19 
respectively.  The results did not appreciably differ by the type or dose of LES 20 
consumed, co-intervention type or fasting glucose and insulin levels.  Among patients 21 
with type 2 diabetes, the mean change difference indicated a smaller PPG response after 22 




Conclusions: Ingestion of LES, administered alone or in combination with a nutrient-24 
containing preload, has no acute effects on the mean change in postprandial glycemic or 25 
insulinemic responses compared to a control intervention.  Apart from a small beneficial 26 
effect on PPG (-0.3 mmol/l) in studies enrolling patients with type 2 diabetes, the effects 27 
did not differ by type or dose of LES, or fasting glucose or insulin levels.   28 
Keywords: Non-caloric sweeteners; Non-nutritive sweeteners; Artificial sweeteners; 29 
Postprandial; Glucose; Insulin; Diabetes 30 





Low-energy sweeteners (LES) are often used to replace sugars in food and beverage 33 
formulations because they can provide sweet taste with little or no energy contribution 34 
or cariogenicity.  As such, a range of different LES are common in the global food 35 
supply (1), and frequently used by manufacturers providing lower calorie or sugar 36 
alternatives to various food and beverage products.  In the United Sates National Health 37 
and Nutrition Examination Survey 2007–2012, about 50% of respondents reported 38 
consuming LES-containing products over a 2-day period (2).    39 
Despite extensive safety evaluations of these compounds by regulatory bodies (3-5), 40 
there is an ongoing debate regarding potential detrimental health effects of LES intake 41 
(6, 7).  Concerns have been expressed, mainly based on selected animal and human 42 
observational studies, that LES consumption may increase risks of metabolic disease, 43 
especially obesity and type 2 diabetes (8-11).  It has been suggested that this might arise 44 
in part as a result of LES stimulation of gut or systemic mechanisms responsive to sweet 45 
stimuli and glucose (5, 11, 12).  However, while LES stimulation of such systems has 46 
mainly been demonstrated in vitro and with animal models, it is uncertain whether these 47 
effects are physiologically relevant in humans (13, 14).  Furthermore, a substantial body 48 
of human intervention data suggests that overall, LES intake has no significant acute or 49 
chronic effects on measures of glucose homeostasis (10, 15-18).   50 
A key question underpinning the putative link between LES and metabolism is the 51 
presence and magnitude of an effect of LES, ingested as part of a non-caloric or caloric 52 
(nutrient-containing) preload, on glycemic responses.  To date there has been no 53 




postprandial glucose (PPG) and insulin (PPI) responses, which is a standard way of 55 
testing for and expressing the systemic glycemic and insulinemic exposures induced by 56 
meals.  Dietary patterns giving higher post-meal glycemic excursions are associated 57 
with increased risk of type 2 diabetes (19, 20), whereas drugs lowering PPG have been 58 
shown to reduce the risk of progression from pre-diabetes to diabetes (19, 21).  Our 59 
objective was therefore to perform an up-to-date systematic review with meta-analysis 60 
of controlled human intervention studies investigating the acute effects of LES intake on 61 
PPG and PPI responses. 62 
Methods 63 
The protocol for this systematic review and meta-analysis was registered in the 64 
international prospective register of systematic reviews (PROSPERO, registration 65 
number: CRD42018099608), and conducted and reported in accordance with the 66 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 67 
statement guidelines (22). 68 
Search strategy 69 
To qualify for inclusion, trials had to meet the pre-defined inclusion criteria outlined 70 
in Table 1.   71 
PubMed/Medline, OVID FSTA, and SCOPUS were searched (from the date of 72 
inception until January 2020) to identify potentially relevant studies conducted in 73 
human participants and published in English.  Titles, abstracts and keywords were 74 
searched for variations and combinations of the following terms: Artificial sweetener(s), 75 




sucralose, aspartame, stevia, steviol, saccharin(e), acesulfame, erythritol, diet(beverage 77 
OR drink OR soda), low calorie(beverage OR drink OR soda)), low-energy(beverage 78 
OR drink OR soda), glucose, insulin and glyc(a)emic (full PubMed search syntax in the 79 
Supplementary Methods).  Bibliographies from obtained publications were also screened 80 
for additional potentially relevant studies.  81 
Screening and selection of trials 82 
A two-step screening and selection process was followed.  During the first step, 83 
titles, abstracts and keywords of publications were screened separately by two of the 84 
authors (AG & DJM) to identify potentially eligible studies.  During the second step, 85 
the full texts of these publications were examined to gauge eligibility based on the 86 
stated inclusion criteria.  In cases of inter-reviewer disagreement, questions on study 87 
eligibility were resolved through consensus and consultation with the other co-authors 88 
(KMA & AR). 89 
Data extraction and quantification 90 
The following information was extracted from eligible publications by means of a 91 
predefined data extraction file: 1) publication details (author, year of publication, 92 
country); 2) study design characteristics (crossover or parallel, blinding); 3) subject 93 
characteristics (age, gender and health status); 4) intervention and control treatment 94 
characteristics (type and dosage of LES, presence and type of meal/nutrient-containing 95 
preload, type of control); 5) postprandial glucose and insulin incremental area under the 96 
curve (iAUC) and associated measures of variance; 6) risk of bias indicators.  If no 97 
iAUC values were reported, postprandial data per measured timepoint were extracted 98 




(23)).  Data were extracted by 2 independent reviewers (AG, DJM) and differences 100 
resolved by consensus. 101 
Data synthesis and statistical analysis 102 
Where postprandial data at individual timepoints were extracted, the iAUC was 103 
calculated by the trapezoidal method (24).  The variances of these iAUCs were based on 104 
the standard deviations (SD) of the respective individual timepoints and, calculated by 105 
means of matrix algebra involving a covariance matrix with the assumed correlation 106 
structure being compound symmetry (25).  For this purpose, the correlation between 107 
timepoints was assumed to be 0.75 for glucose and 0.5 for insulin.  These assumptions 108 
were based on PPG and PPI measurements at repeated timepoints in previous studies 109 
conducted by our group (26-29). 110 
Prior to meta-analysis, all glucose and insulin data were transformed into SI units 111 
(mmol/l for glucose (= 0.0555*mg/dl) and pmol/l for insulin (= 6*µU/ml)).  The 112 
outcomes were expressed as mean postprandial changes by dividing the iAUCs by the 113 
duration of the postprandial measurement period (120 min).  When measures of 114 
variance were not reported, they were imputed using variance data from the other 115 
studies included in the meta-analysis (30).   116 
For both glucose and insulin, the principal effect measure was the difference in the 117 
mean postprandial changes between LES and control interventions.  Pairwise analyses 118 
were applied to all crossover trials as described by Elbourne et al (31).  The weighted 119 
effect estimates and corresponding 95% confidence intervals (CI) were calculated using 120 
random effects models with inverse variance weighting (32) using the PROC MIXED 121 




calculated by means of fixed effects models served as sensitivity analyses.  Several 123 
trials included in the meta-analyses included two or more different comparisons (e.g. 124 
different doses or types of LES) in the same subjects (33-41).  To ensure that these trials 125 
did not contribute a disproportionate weight to the meta-analyses due to double counting 126 
of the same subjects, the weight of each comparison was divided by the total number of 127 
included comparisons in the respective trial (42). 128 
Influence analyses were conducted by systematically excluding one study at a time 129 
and re-analyzing the remaining data to determine whether a specific study was exerting 130 
excessive influence on the overall outcomes.  Where enough data were available, the 131 
potential effects of pre-defined covariates on the overall outcomes were assessed by 132 
means of subgroup (minimum of 4 comparisons per subgroup) and weighted meta-133 
regression analyses (minimum of 10 comparisons per covariate) (43, 44).  The pre-134 
defined covariates were: LES type, health status (healthy; having type 2 diabetes), co-135 
exposure type (i.e. LES consumed in a fasted state; LES consumed with a meal or other 136 
nutrient-containing preload), baseline fasting glucose and insulin and LES dose.   137 
Risk of bias assessment 138 
Assessment of the risk of bias (RoB) in the included studies was done by means of 139 
the Cochrane Collaboration’s tool for assessing RoB (45).  For this purpose, seven 140 
different domains were considered (random sequence generation, allocation 141 
concealment, blinding of participants and personnel, blinding of outcome assessment, 142 
incomplete outcome data, selective reporting and other sources of bias). The 143 
assessments were carried out independently by 2 authors (AG and DJM), and 144 




Publication bias was evaluated by means of visual inspection of funnel plots 146 
(constructed by plotting inverse SE against the respective weighted mean difference in 147 
glucose and insulin iAUC for each trial) and Egger's regression test (with P<0.1 148 
indicating asymmetry) (46).   149 
Heterogeneity was assessed by means of the Cochran’s Q statistic (significant at 150 
P<0.1) and quantified by the I2-statistic (with values of 25%, 50% and 75% considered 151 
to be low-, moderate- and high-level heterogeneity respectively) (47).  In the absence of 152 
a enough studies with head-to-head comparisons of the PPG and PPI effects of the 153 
different LES types included in the review, a post-hoc frequentist network meta-analysis 154 
was conducted in order to study any potential heterogeneity (or informative lack 155 
thereof) in this regard.  Analyses were conducted using the netmeta package on the R 156 
statistical software (48). 157 
 158 
Results 159 
Included trial characteristics 160 
The systematic searches retrieved a total of 5,105 potentially relevant papers after 161 
removal of duplicates (Figure 1).  After exclusion of those that did not meet the pre-162 
defined inclusion criteria, 26 papers remained that were included in the quantitative 163 
synthesis (meta-analysis) (33-41, 49-65).  The 26 included papers reported on 34 trials 164 
(experiments) with information on PPG responses (yielding 55 comparisons) and 29 165 
trials with information on PPI responses (yielding 50 comparisons).  The characteristics 166 




glucose and/or insulin responses for time periods <120 minutes post-prandially were 168 
included in the qualitative synthesis, and are summarized in Supplementary Table 1.   169 
A total of 452 individual participants took part in the 55 comparisons for PPG, and 170 
394 participants in 50 comparisons provided data for PPI.  The number of participants 171 
per comparison ranged from 6 to 31.  Mean age ranged from 18 to 66 years.  Forty-one 172 
comparisons included healthy lean participants.  The remaining 14 comparisons were 173 
comprised of patients with diabetes (n = 9 type 2 diabetes and n = 1 type 1 diabetes) and 174 
participants with obesity but no other health condition (n = 4). 175 
In all comparisons, participants started from a fasting baseline. In 12 comparisons, 176 
LES was administered to participants in a non-caloric vehicle (capsules, water, “diet” 177 
beverage or intragastric infusion).  In the remaining comparisons, LES was 178 
administered either in conjunction with a standardized carbohydrate-containing meal (n 179 
= 23) or a 75g glucose load (n = 20).  The types of LES administered were: sucralose 180 
(13 comparisons), l-arabinose (n = 10), aspartame (n = 9), saccharin (n = 5), erythritol 181 
(n = 3), stevia/steviosides (n = 3), acesulfame potassium (n = 4) and combinations of 182 
sucralose and acesulfame potassium (n = 6), and sucralose, acesulfame potassium and 183 
aspartame (n = 1).  The types of control treatments administered were: water or other 184 
unsweetened beverage (31 comparisons), iso-caloric (and iso-carbohydrate) meals or 185 
beverages without LES (n = 21), saline (n = 2), and corn starch placebo capsules (n = 186 
1).  187 
Effects of LES intake on PPG and PPI responses 188 
In the primary meta-analyses using random effects models, there were no statistically 189 




responses (-0.02 mmol/l mean PPG [95% CI -0.09, 0.05] and -2.39 pmol/l mean PPI 191 
[95%CI -11.83, 7.05] respectively) (Figure 2 and 3).  In meta-analyses using fixed 192 
effects models, the overall estimates of PPG and PPI mean change differences remained 193 
similar (-0.01 mmol/l mean PPG [95% CI -0.04, 0.02] and -1.41 pmol/l mean PPI 194 
[95%CI -4.12, 1.29] respectively). 195 
Meta-regression and subgroup analyses 196 
Meta-regression analyses found no statistically significant influence of baseline 197 
fasting glucose and insulin or dose of LES used, on the mean change differences in PPG 198 
and PPI responses to LES (Table 3).  However, sub-group analyses of health status 199 
(Table 4), indicated a statistically significant difference in the mean change difference 200 
in PPG response to LES when comparing healthy participants and those with type 2 201 
diabetes: thus, there was a small statistically significant reduction in mean PPG for LES 202 
vs control in the type 2 diabetes subgroup (-0.3 mmol/l [95% CI -0.53, -0.07]) whereas 203 
no change was evident in the healthy subgroup (-0.01 mmol/l [95%CI -0.07, 0.06]).  No 204 
further influences on PPG or PPI mean change differences were evident when dividing 205 
studies by LES type or co-exposure type (LES consumed in a non-caloric vs a meal or 206 
nutrient-containing preload). 207 
Influence analyses, assessment of potential biases and heterogeneity 208 
Influence analyses conducted by omitting any single study from the meta-analyses 209 
did not materially affect results for PPG or PPI (Supplementary Table 2).  Overall, all 210 
studies had some risk of bias, most notably regarding blinding (most studies were single 211 
blind as participants could not be blinded due to the nature of the interventions), as well 212 




(Supplementary Table 3).  To evaluate potential effects of (lack of) blinding, a post-hoc 214 
analysis including only the seven trials (16 comparisons)(34, 36, 38, 63, 64) reported as 215 
being double-blind was conducted.  The outcomes of both random and fixed effect 216 
meta-analyses were similar to those of the main analyses (Supplementary Table 4).  217 
Both PPG and PPI mean change differences showed low to moderate heterogeneity 218 
(P value for Q statistic <0.01; I2 = 44.7% and P <0.01, I2 = 48.3% respectively) between 219 
studies.  Egger’s linear regression test did not indicate the potential presence of 220 
publication bias (P value of intercept = 0.48 and 0.83 for PPG and PPI respectively).  In 221 
addition, visual inspection of the funnel plots did not confirm an obvious presence of 222 
publication bias, with the PPG and PPI changes scattered relatively uniformly around 223 
the overall estimates (Figure 4 A and B). 224 
The network meta-analyses produced similar results to the main analyses. For PPG 225 
and PPI mean change differences, there were no direct evidence of an effect of the 226 
different LES types versus each other or the control intervention. For each outcome, the 227 
posterior between-study SD was below 0, suggesting low heterogeneity and 228 
(Supplementary material, Network meta-analysis section).  For stevia, indirect evidence 229 
suggested a smaller PPG response compared to control -0.79 mmol/l [95%CI -1.56; -230 
0.02], sucralose -0.81 mmol/l [95%CI -1.59; -0.02], aspartame -0.82 mmol/l [95%CI -231 
1.60; -0.04], erythritol -0.87 mmol/l [95%CI -1.65; -0.09] and the combination of 232 







This meta-analysis quantifying evidence from 34 randomized controlled intervention 237 
trials found that intake of LES had no statistically significant effects on the mean 238 
change differences in acute post-prandial glucose or insulin responses compared with a 239 
control intervention.  Our findings for LES in a non-caloric (e.g. water) vehicle are in 240 
accordance with the outcome of a recent meta-analysis that found no acute effects on 241 
PPG measured over a range of postprandial time periods (15), as well as another recent 242 
systematic review of PPG responses to LES (84). This is now confirmed based on a 243 
standard 120 min postprandial period of analysis for glucose and for insulin as well.  A 244 
somewhat older network meta-analysis that compared the effects of different caloric and 245 
non-caloric sweeteners on 120 min PPG responses, concluded that the data were 246 
inconclusive (85); however, many relevant trials have been published since that 247 
analysis, which included only two of the 34 trials here.  248 
LES are often consumed in conjunction with caloric nutrients i.e. protein, fat and 249 
carbohydrates.  As such, for the first time, our meta-analysis also included studies where 250 
LES were administered along with standardized mixed meals, carbohydrate-containing 251 
beverages or a 75g glucose preload.  In this regard, sub-group analyses found a similar 252 
absence of effect of LES on the mean change differences in PPG and PPI when 253 
consumed either with or without a carbohydrate or nutrient containing preload.  This 254 
suggests that nutrient and/or food matrix interactions probably do not play a role in 255 
determining potential effects of LES intake on acute glycemic responses.   256 
The outcomes of the 18 studies in which glucose and/or insulin responses were 257 




results of our meta-analyses.  Most studies reported no effects (67, 69-78, 83) or very 259 
small changes (70, 74, 76) in PPG and PPI responses after LES ingestion.   260 
The findings of the few included trials of immediate cephalic phase responses were 261 
inconsistent, with four of these (66, 68, 79, 82) reporting no effects on glucose or 262 
insulin, and two (80, 81) reporting increased cephalic phase PPI responses but no effects 263 
on PPG.  This is noteworthy since, although effects of sweetness itself have been 264 
suggested (86, 87), it would seem that sweet taste stimuli alone are not sufficient to 265 
elicit meaningful acute glycemic responses.  A recent systematic review of studies 266 
utilizing pre-ingestive sweet taste stimulation designs, also suggested that oral sweet 267 
taste activation from LES has limited effects on human glucose homeostasis (84). 268 
Meta-analyses of data from some observational studies suggest an association 269 
between LES intake and an increased risk of developing metabolic diseases, particularly 270 
type 2 diabetes (8, 9).  However, difficulties in the accurate assessment of LES exposure 271 
and problems with reverse causality and confounding factors raise concerns regarding 272 
the reliability and interpretation of associations from observational studies (88-90).  273 
Conversely, our meta-analysis and other reviews (15, 84), show that data from human 274 
intervention studies suggest no effects of LES intake on postprandial glucose responses.   275 
We note, however, that among patients with type 2 diabetes, the mean change difference 276 
indicated a smaller PPG response after exposure to LES vs. control.  Similar effects were also 277 
noted in the meta-analysis of Nichol et al. (15).  This might suggest a potential direct 278 
glucose-lowering benefit of LES intake for these individuals.  However, effect sizes are 279 
small and were found from only 9 comparisons, all of which were judged to be of high 280 




whether the 0.3 mmol/l reduction in PPG response is truly replicable or would be of any 282 
long-term clinical relevance in diabetes management.  A number of longer-term trials of 283 
LES show no significant effects on glycemic control in this population (16).  We have 284 
no obvious explanation or hypothesis for any differential response in the short term, 285 
although this could be related to the poorer glycemic control in people with diabetes. 286 
Several limitations of this meta-analysis should be noted.  Firstly, we did not have an 287 
a priori hypothesis that different types of LES would differ in their effects on the mean 288 
change in PPG or PPI responses.  We therefore assumed that it was appropriate to pool 289 
the effects of different LES types in the same meta-analysis.  Concerns have however 290 
been raised that different LES types might differ in the physiological effects (91).  As 291 
such, a network meta-analysis might therefore have been a more appropriate approach.  292 
Network meta-analysis allows for the pooling of outcomes derived from direct and 293 
indirect evidence across multiple different treatments while preserving the benefits of 294 
randomized comparisons within each trial.  We did conduct a post hoc network meta-295 
analysis to study any potential informative (lack of) heterogeneity in this regard.  The 296 
outcomes were in line with our main analyses, suggesting no direct evidence of a 297 
difference in PPG or PPI effects for the different LES types versus each other or a 298 
control treatment.  The outcome of this analysis should be interpreted with caution 299 
however, since it was conducted after the studies, data and outcomes of the main 300 
analyses were known.   301 
Secondly, most of the included studies had relatively small sample sizes, potentially 302 
obscuring possible intervention effects due to a lack of statistical power.  However, 303 
small study biases are generally associated with the erroneous overestimation of effect 304 




of the interventions, only a small number of the included studies that had specific design 306 
considerations (i.e. administration via capsules/gastric infusion or concomitantly with 307 
glucose/sucrose) were double-blinded.  It is possible that detection bias has occurred in 308 
studies where the participants and, in some cases, the investigators were not blinded as 309 
to the treatments.  However, a post-hoc analysis including only the studies reported as 310 
being double-blind had outcomes similar to those of the main analyses.  This suggests 311 
that potential performance bias was likely not an issue in this case.  Regarding the 312 
subgroup and post-hoc analyses, another potential limitation is that many aspects of the 313 
studies covary.  For example, all of the double-blind studies were conducted in healthy 314 
subjects whereas all of the studies in subjects with type 2 diabetes were not blinded 315 
(potentially high risk of performance bias), and all of the sucralose and l-arabinose 316 
studies are relatively recent whereas most of the aspartame and saccharin studies are 317 
older.  As such, the outcomes of the sub-group analyses should be interpreted with 318 
caution.  Lastly, most of the studies included in this meta-analysis investigated the 319 
effects of a single LES administered alone.  No differences were found based on LES 320 
type, but many current food and beverage products contain combinations of two or more 321 
types of LES.  We only had enough data to perform a sub-group analysis on one 322 
potential combination (acesulfame potassium + sucralose).  Our conclusions in this 323 
regard can, therefore, not be extrapolated to other combinations of LES.  There is, 324 
however, currently no evidence or reasonable explanatory hypothesis as to why the 325 
intake of a combination of LES would have different effects on glucose homeostasis 326 
compared with a single LES alone. 327 
In conclusion, this review provides an up-to-date overview of controlled human 328 




and insulinemic responses.  Our analyses indicate that under acute conditions, whether 330 
administered alone or in combination with a nutrient-containing load, LES do not exert 331 
an independent effect on the mean change in postprandial blood glucose or insulin 332 
responses compared to a control intervention.  Some small reductions in PPI, based on 333 
limited studies, were found in studies enrolling patients with type 2 diabetes, but overall 334 
the null results do not seem to differ appreciably by the type of LES consumed, dose of 335 
LES, or fasting glucose or insulin levels.  A post-hoc network meta-analysis suggested 336 
no direct evidence of a difference in PPG or PPI effects for the different LES types 337 
versus each other or a control treatment.  In light of concerns that different LES types 338 
may differ in their physiological effects, future work adopting an a priori network meta-339 
analysis approach is recommended. 340 
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Table 1. Trial selection criteria. 
Inclusion Exclusion 
Participants/population  
Human children (3-10 years of age), adolescents (10-18 years of 
age) and adults (≥18 years of age);  
 
Healthy participants and those with impaired glucose homeostasis 
(i.e. prediabetes, diabetes type 1 or 2, impaired glucose tolerance 
and overweight or obese individuals) 
Hospitalized/critically ill patients 
Intervention  
Acute exposure to LES; either alone, in water, as diet beverage or 
intragastric infusion, or with a meal or other nutrient-containing 
preloads 
Co-intervention with insulin or drugs affecting glucose 
homeostasis 
Comparators  
The same intervention without inclusion of LES  
Outcomes  
Acute postprandial blood glucose response (defined as incremental 
Area Under the Curve) after exposure to LES or Control 
Trials measuring postprandial blood glucose or insulin responses 
for < 120 min (for quantitative meta-analysis only) 
Acute postprandial insulin response (defined as incremental Area 







Table 2. Characteristics of studies included in the meta-analysis 








LES type LES dose 
(mg) 
Control Meal test Meal carbohydrate 
content (g) 
Outcome 
Ahmad, 2018 (49) 
[Pakistan] 
CO, S 20 24.1 Healthy Stevia 3000 Isocaloric 
meal 
Mixed meal 50 PPG 
Azari, 2017 (50) 
[US] 
CO, S 10 33.5 Healthy Saccharin 18 Water 75g glucose 75 PPG, PPI 
Brown, 2009 (51) 
[US] 
CO, BNR 22 18.5 Healthy Sucralose + Acesulfame K 45.6; 25.9 Carbonated 
water 
75g glucose 75 PPI 
Brown, 2012 (52) 
[US] 
CO, BNR 25 18.8 Healthy Sucralose + Acesulfame K 45.6; 25.9 Carbonated 
water 
75g glucose 75 PPG 
9 18.2 T1D 
10 17.9 T2D 
Burns, 1991 (33) 
[US] 
CO, BNR 8 26.1 Healthy Aspartame 500 Unsweetened 
beverage 
100g sucrose 100 PPG, PPI 
None 0 
Cooper, 1988 (53) 
[Australia] 
CO, BNR 17 62.2 T2D Saccharin 93* Isocaloric 
meal 
Mixed meal 47 PPG, PPI 
Ford, 2011 (54) 
[UK] 












LES type LES dose 
(mg) 
Control Meal test Meal carbohydrate 
content (g) 
Outcome 
Gregersen, 2004 (55) 
[Denmark] 




CO, D 17 22.5 Healthy L-Arabinose 2900 Isocaloric 
meal 














Helou, 2019 (64) 
[Lebanon] 
CO, D 15 20.1 Healthy Acesulfame K 3500 Isocaloric 
meal 
Mixed meal 116 PPG, PPI 
15 21.7 Obese  3500 
           












LES type LES dose 
(mg) 
Control Meal test Meal carbohydrate 
content (g) 
Outcome 
Horwitz 1988, (35) 
[US] 
CO, O 12 28 Healthy Aspartame 400 Unsweetened 
beverage 
Fasted 0 PPG, PPI 
Saccharin 135 





CO, D 15 25 Healthy L-Arabinose 1000 Isocaloric 
beverage 
75g sucrose 75 PPG, PPI 
2000 
3000 
Ma, 2009 (37) 
[Australia] 
CO, S 7 24 Healthy Sucralose 800 Saline Fasted 0 PPG, PPI 
80 
Nichol, 2020 (65) 
[US] 
CO, BNR 10 27 Healthy Sucralose 48 Water 75g glucose 75 PPG, PPI 
11 29.5 Obese 
Overduin, 2016 (56) 
[UK] 
CO, S 10 33.4 Healthy Erythritol 8000 Isocaloric 
meal 
Mixed meal NR PPG, PPI 




CO, BNR 6 NR T2D Stevia 2000 Isocaloric 
meal 












LES type LES dose 
(mg) 
Control Meal test Meal carbohydrate 
content (g) 
Outcome 
Pepino, 2013 (58) 
[US] 




CO, BNR 24 23.2 Healthy Aspartame 270 Isocaloric 
meal 
Mixed meal 90 PPG, PPI 
Slama, 1984 (60) 
[France] 
CO, BNR 12 51-57 T2D Saccharin 40 Isocaloric 
meal 
Mixed meal 70 PPG, PPI 
Solomi, 2019 (61) 
[UK] 
CO, BNR 10 27.2 Healthy Aspartame + Acesulfame K 
(Diet Coke) 
55.9; 38.5† Water 25g glucose 25 PPG 
Steinert, 2011 (38) 
[Switzerland] 
CO, D 12 23.3 Healthy Acesulfame K 220 Water Fasted 0 PPG, PPI 
Aspartame 169 
Sucralose 62 
           
           
           












LES type LES dose 
(mg) 
Control Meal test Meal carbohydrate 
content (g) 
Outcome 
Sylvetsky, 2016 (39) 
[US] 
CO, BNR 30 29.7 Healthy Sucralose 68 Water 75g glucose 75 PPG, PPI 
170 
205 
31 27.4 Healthy Sucralose + Acesulfame K 
(Diet Rite Cola) 
68; 41 Carbonated 
water 
75g glucose 75 PPG, PPI 
Sucralose + Acesulfame K 
+ Aspartame (Diet 
Mountain Dew) 
18; 18; 57 
Sucralose + Acesulfame K 68; 41 
Temizkan, 2015 (40) 
[Turkey] 
CO, S 8 45 Healthy Aspartame 72 Water 75g glucose 75 PPG, PPI 
Sucralose 24 













LES type LES dose 
(mg) 
Control Meal test Meal carbohydrate 
content (g) 
Outcome 
Wolf-Novak, 1990 (62) 
[US] 
CO, BNR 7 27 Healthy Aspartame 200 Isocaloric 
beverage 




CO, D 20 25.9 Healthy Erythritol 75000 Water Fasted 0 PPG, PPI 
Wu, 2016 (41) 
[Australia] 
CO, S 10 33.6 Healthy Acesulfame K 200 Water 75g glucose 75 PPG, PPI 
Sucralose + Acesulfame K 46; 26 
Sucralose 52 
*dose not given but reported as equivalent sweetness to 28g sucrose; dose calculated considering a sweetness equivalence of 300:1 
†dose not reported; estimated according to content of Aspartame + Acesulfame K in commercially sold diet cola 
BNR: Blinding not reported; CO: Cross-over study design; D: Double-blind; PPG: Postprandial glucose; PPI: Postprandial insulin; LES: Low energy sweetener; NR: 




Table 3. Impact of continuous covariates on PPG and PPI responses to LES 
Covariates Mean change difference in PPG Mean change difference in PPI 
 β SE P β SE P 
Baseline fasting glucose (per 1 mmol/l increase) -0.059 0.04 0.15 2.17 2.87 0.45 
Baseline fasting insulin (per 1 pmol/l increase) -0.001 0.001 0.32 -0.04 0.11 0.75 
Sucralose dose (per 10 mg increase) 0.004 0.003 0.22 0.08 0.19 0.66 
L-Arabinose dose (per 1000 mg increase) 0.001 0.024 0.96 0.96 3.93 0.81 





Table 4. Mean change difference in PPG and PPI after LES intake within different subgroups. 





(mmol/l) 95% CI 
P within 
subgroup 





(pmol/l) 95% CI 
P within 
subgroup 
I2 Chi2 df P between 
subgroups 
LES type      7.11 6 0.31      2.57 6 0.86 
Sucralose 13 0.05  -0.07, 0.18 0.40 33.45 
   
13 -3.58 -21.06; 13.90 0.69 12.99 
   
L-Arabinose 10 -0.03 -0.22, 0.16 0.77 34.91 
   
10 -6.90 -32.63; 18.83 0.60 45.41 
   
Aspartame 9 0.05 -0.09, 0.20 0.46 0 
   
9 1.82 -13.27; 16.92 0.81 49.51 
   
Sucralose + 
Ace K 
6 0.12 -0.14, 0.38 0.36 0 
   
4 25.32 -24.28; 74.92 0.32 0 
   
Saccharin 5 -0.04 -0.20, 0.13 0.66 0 
   
5 -0.29 -17.03; 16.44 0.97 0 
   
Ace K 4 -0.12 -0.29, 0.05 0.16 0 
   
4 2.74 -21.07; 26.54 0.82 0 
   




12 0.02 -0.11, 0.15 0.76 
44.8    
12 
-0.57 -15.85, 14.71 0.94 
0 
   
With nutrient 
preload 
43 -0.03 -0.11, 0.04 0.40 
41.46    
38 
-3.48 -15.38, 8.42 0.57 
56.31 
   
Health status      5.56 1 0.02*      0.45 1 0.5 
Healthy 41 -0.01 -0.07, 0.06 0.80 36.31    39 -2.86 -12.01, 6.30 0.54 56.31    
Type 2 
diabetes 
9 -0.30 -0.53, -0.07 0.01* 
32.69    
7 
4.87 -15.63, 25.37 0.64 
18.67 
   






Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram of the study selection procedure. 
Figure 2. Forest plot showing mean change difference in PPG after LES intake.  
Horizontal lines represent 95% confidence intervals.  The diamond represents the 
pooled estimate determined using a random effects model. 
Figure 3. Forest plot showing mean change difference in PPI after LES intake.  
Horizontal lines represent 95% confidence intervals.  The diamond represents the 
pooled estimate determined using a random effects model. 
Figure 4. Funnel plot used to assess risk of publication bias for (A) PPG and (B) PPI.  
Weights (1/SE2) are plotted against the changes in PPG (A) and PPI (B) from a total of 
55 comparisons (452 individual participants) for PPG and 50 comparisons for PPI (394 
individual participants) respectively. Both PPG and PPI effects showed moderate 
heterogeneity (P value for Q statistic <0.01; I2 = 59.5% and P <0.01, I2 = 61.2% 
respectively) between studies. 
 
